These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 880966)

  • 1. Effective antitumour conjugates of alkylating drug and antibody using dextran as the intermediate carrier.
    Rowland GF
    Eur J Cancer (1965); 1977 Jun; 13(6):593-6. PubMed ID: 880966
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibodies as carriers for oncostatic materials.
    Arnon R; Hurwitz E; Sela M
    Recent Results Cancer Res; 1980; 75():236-45. PubMed ID: 6165055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect in vivo of chemotherapeutic drug--antibody conjugates in two murine experimental tumor systems.
    Hurwitz E; Maron R; Bernstein A; Wilchek M; Sela M; Arnon R
    Int J Cancer; 1978 Jun; 21(6):747-55. PubMed ID: 669855
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage.
    Rowland GF; O'Neill GJ; Davies DA
    Nature; 1975 Jun; 255(5508):487-8. PubMed ID: 1138199
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems.
    Wall ME; Abernethy GS; Carroll FI; Taylor DJ
    J Med Chem; 1969 Sep; 12(5):810-8. PubMed ID: 5812193
    [No Abstract]   [Full Text] [Related]  

  • 6. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies.
    Bernstein A; Hurwitz E; Maron R; Arnon R; Sela M; Wilchek M
    J Natl Cancer Inst; 1978 Feb; 60(2):379-84. PubMed ID: 621754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selectivity of the antitumor action of 2 alkylating compounds with different carrier structures].
    Astardzhieva Z; Stoichkov I
    Eksp Med Morfol; 1988; 27(2):14-7. PubMed ID: 3168903
    [No Abstract]   [Full Text] [Related]  

  • 8. 3-N,N-bis(2-chloroethylamino)p-toluic acid, a new cytostatic drug active in cancer.
    Dobre V; Maltezeanu G
    Cancer Chemother Rep; 1970 Oct; 54(5):319-23. PubMed ID: 5514620
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.
    Smyth MJ; Pietersz GA; Farquhar I; McKenzie C
    Targeted Diagn Ther; 1988; 1():123-56. PubMed ID: 2979055
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies of the growth of an ascitic tumour. II. A system to study the tumour-age dependent effect of antitumour agents.
    Kopper L; Jeney A; Lapis K; Török M
    Eur J Cancer (1965); 1978 Jan; 14(1):75-82. PubMed ID: 624305
    [No Abstract]   [Full Text] [Related]  

  • 11. The need for additional alkylating agents.
    Connors TA
    Cancer Res; 1969 Dec; 29(12):2433-7. PubMed ID: 5369691
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anti cancer effect of antibiotic-AFP-purified antibody conjugates].
    Tsukada Y; Hibi N; Ohkawa K; Uchino J; Hirai H
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2653-8. PubMed ID: 6210058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexes and conjugates of cis-Pt for immunotargeted chemotherapy.
    Arnon R; Schechter B; Wilchek M
    Adv Exp Med Biol; 1991; 303():79-90. PubMed ID: 1725240
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of a mouse hepatoma by the alkylating agent Trenimon linked to immunoglobulins.
    Ghose T; Guclu A; Raman RR; Blair AH
    Cancer Immunol Immunother; 1982; 13(3):185-9. PubMed ID: 6925984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine 3',5'-monophosphate phosphodiesterase activity in experimental animal tumours which are either sensitive or resistant to bifunctional alkylating agents.
    Tisdale MJ; Phillips BJ
    Biochem Pharmacol; 1975 Jan; 24(2):205-10. PubMed ID: 163093
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the mechanism of action of the tumour inhibitory triazenes.
    Audette RC; Connors TA; Mandel HG; Merai K; Ross WC
    Biochem Pharmacol; 1973 Aug; 22(15):1855-64. PubMed ID: 4722457
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential antitumor agents: steroidal amidoesters with an alkylating moiety.
    Papageorgiou A; Boutis L; Nicolaropoulos S; Catsoulacos P
    Oncology; 1987; 44(2):128-32. PubMed ID: 3574853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors.
    Schabel FM
    Cancer Res; 1969 Dec; 29(12):2384-9. PubMed ID: 5369685
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative antitumor effects of peptichemio and other alkylating agents.
    Schmid FA; Banks SE; Stock CC
    Cancer Treat Rep; 1977; 61(3):473-5. PubMed ID: 872145
    [No Abstract]   [Full Text] [Related]  

  • 20. Experimental cancer chemotherapy: strategy for cure.
    Cain BF
    N Z Med J; 1971 Feb; 73(465):85-90. PubMed ID: 4994879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.